Yifei Huang Emilia, Hansen Anne Vejen, Tidemandsen Casper, la Cour Freiesleben Nina, Nielsen Henriette Svarre, Backer Vibeke, Ulrik Charlotte Suppli
Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Copenhagen, Denmark.
Department of Obstetrics and Gynaecology, the Fertility Clinic, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark.
Eur Clin Respir J. 2023 Jun 10;10(1):2221376. doi: 10.1080/20018525.2023.2221376. eCollection 2023.
We investigate symptoms of anxiety and depression among women with asthma prior to fertility treatment.
This is a cross-sectional study of women screened for eligibility to the PRO-ART study (RCT of omalizumab versus placebo in asthmatic women undergoing fertility treatment (NCT03727971)). All participants were scheduled for in vitro fertilization (IVF) treatment at four public fertility clinics in Denmark. Data on demographics and asthma control (ACQ-5) were obtained. Symptoms of anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS-A and D, respectively) and defined as being present on both subscales if a score >7 was obtained. Spirometry, diagnostic asthma test, and measurement of fractional exhaled nitric oxide (FeNO) were conducted.
A total of 109 women with asthma were included (mean age 31.8 ± 4.6 and BMI 25.5 ± 4.6). Most women had male factor infertility (36.4%) or unexplained infertility (35.5%). Twenty-two percent of the patients reported uncontrolled asthma (ACQ-5 score > 1.5). The mean HADS-A and HADS-D scores were 6.0 ± 3.8 (95% CI 5.3-6.7) and 2.5 ± 2.2 (95% CI 2.1-3.0), respectively. Thirty (28.0%) women reported anxiety symptoms, and four (3.7%) had concomitant depressive symptoms. Uncontrolled asthma was significantly associated with both depressive ( = 0.04) and anxiety symptoms ( = 0.03).
More than 25% of women with asthma prior to fertility treatment had self-reported symptoms of anxiety, and just below 5% had self-reported depressive symptoms, possibly related to uncontrolled asthma.
我们调查了接受生育治疗前哮喘女性的焦虑和抑郁症状。
这是一项对筛选出符合PRO-ART研究（在接受生育治疗的哮喘女性中进行奥马珠单抗与安慰剂对比的随机对照试验，NCT03727971）资格的女性进行的横断面研究。所有参与者均计划在丹麦的四家公立生育诊所接受体外受精（IVF）治疗。获取了人口统计学数据和哮喘控制情况（ACQ-5）。使用医院焦虑抑郁量表（分别为HADS-A和HADS-D）评估焦虑和抑郁症状，若得分>7，则定义为两个子量表上均存在症状。进行了肺功能测定、诊断性哮喘测试以及呼出一氧化氮分数（FeNO）测量。
共纳入109名哮喘女性（平均年龄31.8±4.6岁，体重指数25.5±4.6）。大多数女性存在男性因素不孕（36.4%）或不明原因不孕（35.5%）。22%的患者报告哮喘控制不佳（ACQ-5得分>1.5）。HADS-A和HADS-D的平均得分分别为6.0±3.8（95%置信区间5.3 - 6.7）和2.5±2.2（95%置信区间2.1 - 3.0）。30名（28.0%）女性报告有焦虑症状，4名（3.7%）有伴随的抑郁症状。哮喘控制不佳与抑郁症状（P = 0.04）和焦虑症状（P = 0.03）均显著相关。
超过25%的接受生育治疗前的哮喘女性自我报告有焦虑症状，略低于5%的女性自我报告有抑郁症状，这可能与哮喘控制不佳有关。
